Table 1 Information on the some of the nanoparticle-based SARS-CoV-2 vaccines that are in phase-4, phase-3 of clinical trials [133, 134]
Phase | Vaccine name | Type of vaccine | Developer |
|---|---|---|---|
Phase 4 | CoronaVac | Inactivated virus | Sinovac |
Phase 4 | Spikevax | RNA based vaccine | Moderna |
Phase 4 | BNT162b2 | RNA based vaccine | Pfizer/BioNTech |
Phase 4 | Ad5-nCoV-IH | Viral vector (non-replicating) | CanSino Biological Inc./Beijing Institute of Biotechnology |
Phase 4 | Ad26.COV2.S | Viral vector (non-replicating) | Janssen Pharmaceutical |
Phase 4 | MVC-COV1901 | Protein subunit | Medigen Vaccine Biologics |
Phase 3 | Nanovax | Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax) | Nanogen Pharmaceutical Biotechnology |
Phase 3 | SCB-2019 | Protein subunit | Clover Biopharmaceuticals Inc./Dynavax |
Phase 3 | UB-612 | Protein subunit | Vaxxinity |
Phase 3 | GBP510 | Protein subunit | SK Bioscience Co., Ltd. |